Design and Implementation Issues of an Information System Supporting Cervical Cancer Screening Programs

Cervical cancer is one of the most common women mortality reasons in the world. However it is a well studied disease with known natural history that can be prevented and treated if diagnosed in early stage. The key to prevention is the regular check of all women fulfilling specific criteria with test Papanikolaou, this process is called population based cervical cancer screening program. As the involved population is very large, critical to the success of the program is the organization and quality control and assurance. Unavoidable a computerized information system supporting the program must be in place. Aim of this article is to present aspects of the architecture, design and implementation of an information system supporting the Hellenic Cervical Cancer Screening Program. Within the framework of the Hellenic national program against cancer and especially for the

[1]  G. Koliopoulos,et al.  High-risk human papillomavirus DNA test and p16(INK4a) in the triage of LSIL: a prospective diagnostic study. , 2011, Gynecologic oncology.

[2]  J. Val-Bernal,et al.  A type‐specific study of human papillomavirus prevalence in cervicovaginal samples in three different Spanish regions , 2009, APMIS : acta pathologica, microbiologica, et immunologica Scandinavica.

[3]  A. Jemal,et al.  Global Cancer Statistics , 2011 .

[4]  Thomas Wetter,et al.  Artificial neural network may perform good to predict the survivability of cervical cancer , 2006, AMIA.

[5]  C. Poole,et al.  Persistent human papillomavirus infection and cervical neoplasia: a systematic review and meta-analysis. , 2008, American journal of epidemiology.

[6]  A. Spathis,et al.  Identification of Women for Referral to Colposcopy by Neural Networks: A Preliminary Study Based on LBC and Molecular Biomarkers , 2012, Journal of biomedicine & biotechnology.

[7]  E. Franco,et al.  Persistent human papillomavirus infection and cervical neoplasia. , 2002, The Lancet. Oncology.

[8]  D. Grobbee,et al.  Less medical intervention after sharp demarcation of Grade 1‐2 cervical intraepithelial neoplasia smears by neural network screening , 2001, Cancer.

[9]  Maria Rosaria Giovagnoli,et al.  Cervical False Negative Cases Detected by Neural Network–Based Technology , 2002, Acta Cytologica.

[10]  G. Koliopoulos,et al.  Clinical management of HPV‐related disease of the lower genital tract , 2010, Annals of the New York Academy of Sciences.

[11]  S. Franceschi,et al.  Human papillomavirus type distribution in invasive cervical cancer and high‐grade cervical lesions: A meta‐analysis update , 2007, International journal of cancer.

[12]  M. Kyrgiou,et al.  The Evaluation of p16ink4a Immunoexpression/Immunostaining and Human Papillomavirus DNA Test in Cervical Liquid-Based Cytological Samples , 2010, International Journal of Gynecologic Cancer.

[13]  B. Patterson,et al.  High-throughput cervical cancer screening using intracellular human papillomavirus E6 and E7 mRNA quantification by flow cytometry. , 2005, American journal of clinical pathology.

[14]  T. Kelesidis,et al.  Human papillomavirus (HPV) detection using in situ hybridization in histologic samples: correlations with cytologic changes and polymerase chain reaction HPV detection. , 2011, American journal of clinical pathology.

[15]  J. Smith Bethesda 2001 , 2002, Cytopathology : official journal of the British Society for Clinical Cytology.

[16]  K. Syrjänen,et al.  Cervical cancer screening in Mediterranean countries: implications for the future , 2010, Cytopathology : official journal of the British Society for Clinical Cytology.

[17]  Petros Karakitsos,et al.  A preliminary study of the potential of tree classifiers in triage of high-grade squamous intraepithelial lesions. , 2011, Analytical and quantitative cytology and histology.

[18]  S. Adalsteinsson,et al.  Trends in cervical and breast cancer in Iceland. A statistical evaluation of trends in incidence and mortality for the period 1955–1989, their relation to screening and prediction to the year 2000 , 1991, International journal of cancer.

[19]  P. Martin-Hirsch,et al.  Commentary: Have we dismissed ablative treatment too soon in colposcopy practice? , 2006, BJOG : an international journal of obstetrics and gynaecology.

[20]  D. Solomon,et al.  The Bethesda system for reporting cervical cytology : definitions, criteria, and explanatory notes , 2004 .

[21]  P. Martin-Hirsch,et al.  Alterations in human papillomavirus-related biomarkers after treatment of cervical intraepithelial neoplasia. , 2011, Gynecologic oncology.

[22]  D. McCance Human papillomavirus (HPV) infections in the aetiology of cervical cancer. , 1988, Cancer surveys.

[23]  Fred Russell Kramer,et al.  Multicolor molecular beacons for allele discrimination , 1998, Nature Biotechnology.

[24]  N. Agnantis,et al.  The natural history of HPV infection of the uterine cervix. Long-term observational and histological data. , 2002, Anticancer research.

[25]  O. F. Kraushaar,et al.  The Papanicolaou test in the cancer control program. , 1949, The Journal of the Kansas Medical Society.

[26]  M. Boon,et al.  Consequences of neural network technology for cervical screening: Increase in diagnostic consistency and positive scores , 1996, Cancer.

[27]  A. Spathis,et al.  Promoter Methylation of p16INK4A, hMLH1, and MGMT in Liquid-Based Cervical Cytology Samples Compared with Clinicopathological Findings and HPV Presence , 2011, Infectious diseases in obstetrics and gynecology.

[28]  M. von Knebel Doeberitz,et al.  p16INK4a Immunohistochemistry Improves Interobserver Agreement in the Diagnosis of Cervical Intraepithelial Neoplasia , 2002, The American journal of surgical pathology.

[29]  A. Malik The role of human papilloma virus (HPV) in the aetiology of cervical cancer. , 2005, JPMA. The Journal of the Pakistan Medical Association.

[30]  G. Koliopoulos,et al.  Human papillomavirus DNA and mRNA positivity of the anal canal in women with lower genital tract HPV lesions: predictors and clinical implications. , 2011, Gynecologic oncology.

[31]  M. Kyrgiou,et al.  The role of p16(INK4a) immunostaining in the risk assessment of women with LSIL cytology: a prospective pragmatic study. , 2011, European journal of gynaecological oncology.

[32]  McCance Dj Human papillomavirus (HPV) infections in the aetiology of cervical cancer. , 1988 .

[33]  T. Rohan,et al.  Persistent human papillomavirus infection as a predictor of cervical intraepithelial neoplasia. , 2001, JAMA.

[34]  Pekka Nieminen,et al.  Prospective and randomised public‐health trial on neural network‐assisted screening for cervical cancer in Finland: Results of the first year , 2003, International journal of cancer.

[35]  A. Spathis,et al.  Genetic Variability and Phylogeny of High Risk HPV Type 16, 18, 31, 33 and 45 L1 Gene in Greek Women , 2011, International journal of molecular sciences.

[36]  J. Bourhis,et al.  Association between poor prognosis in early-stage invasive cervical carcinomas and non-detection of HPV DNA , 1990, The Lancet.

[37]  A. Spathis,et al.  Clinical performance of human papillomavirus E6, E7 mRNA flow cytometric assay compared to human papillomavirus DNA typing. , 2011, Analytical and quantitative cytology and histology.

[38]  M. Henry The Bethesda System 2001: an update of new terminology for gynecologic cytology. , 2003, Clinics in laboratory medicine.